Results of Phase III ReMoxTB Clinical Trial Published
Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a [...]
TB R&D Update: Scientists discover a new resistance mechanism to second line drug Bedaquiline
Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB.